The National Pharmaceutical Pricing Authority (NPPA) has issued FAQs explaining its initiative to cap trade margins at 30% for 137 specified non-scheduled anti-cancer medicines. Effective 9 November 2026, the measure aims to reduce excessive supply-chain markups and improve affordability. The FAQs clarify the medicines covered, pricing implications, responsibilities of hospitals and pharmacies, price-checking methods, and complaint mechanisms.
The FAQs provide guidance on NPPA’s trade margin rationalisation initiative, which caps trade margins at 30% for 137 specified non-scheduled anti-cancer medicines listed in Table B of the relevant notification. The revised pricing mechanism will take effect from 9 November 2026 and remain in force until further orders.
Key points include:
- The cap applies to both branded and generic versions of the covered formulations; it does not mean that every medicine will become 30% cheaper.
- Permissible MRPs may vary by brand, strength, dosage form and pack size, depending on the applicable pricing formula.
- Patients can check revised prices through medicine packaging, retailer or hospital price lists, manufacturer information, the NPPA website and Pharma Sahi Daam.
- Hospitals, medical institutions, retailers and dealers must comply with applicable pricing and price-display requirements. Hospitals and medical institutions must also prominently display revised prices on their websites.
- Patients can report overcharging through Pharma Sahi Daam, NPPA email or helpline, or the concerned State Drug Controller.
